CN113577099A - Use of molybdenum and/or tungsten containing compounds against Human Papilloma Virus (HPV) or herpes virus (HSV) and pharmaceutical compositions thereof - Google Patents
Use of molybdenum and/or tungsten containing compounds against Human Papilloma Virus (HPV) or herpes virus (HSV) and pharmaceutical compositions thereof Download PDFInfo
- Publication number
- CN113577099A CN113577099A CN202110961745.4A CN202110961745A CN113577099A CN 113577099 A CN113577099 A CN 113577099A CN 202110961745 A CN202110961745 A CN 202110961745A CN 113577099 A CN113577099 A CN 113577099A
- Authority
- CN
- China
- Prior art keywords
- hpv
- virus
- molybdenum
- tungsten
- hsv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052721 tungsten Inorganic materials 0.000 title claims abstract description 71
- 239000010937 tungsten Substances 0.000 title claims abstract description 70
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 title claims abstract description 69
- 241000701806 Human papillomavirus Species 0.000 title claims abstract description 65
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 title claims abstract description 56
- 239000011733 molybdenum Substances 0.000 title claims abstract description 56
- 241001529453 unidentified herpesvirus Species 0.000 title claims abstract description 55
- 229910052750 molybdenum Inorganic materials 0.000 title claims abstract description 53
- 150000001875 compounds Chemical class 0.000 title claims abstract description 39
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 39
- 241000700605 Viruses Species 0.000 claims abstract description 18
- 239000000499 gel Substances 0.000 claims description 61
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 claims description 21
- 239000002245 particle Substances 0.000 claims description 18
- 229910000476 molybdenum oxide Inorganic materials 0.000 claims description 14
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 12
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 12
- 241000701828 Human papillomavirus type 11 Species 0.000 claims description 11
- 241001631646 Papillomaviridae Species 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 8
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 8
- 241000701041 Human betaherpesvirus 7 Species 0.000 claims description 8
- 241000701027 Human herpesvirus 6 Species 0.000 claims description 8
- 239000011159 matrix material Substances 0.000 claims description 8
- 229910001930 tungsten oxide Inorganic materials 0.000 claims description 8
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims description 6
- 241000709701 Human poliovirus 1 Species 0.000 claims description 6
- 241000709727 Human poliovirus 3 Species 0.000 claims description 6
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 241000709704 Human poliovirus 2 Species 0.000 claims description 5
- 241000700584 Simplexvirus Species 0.000 claims description 5
- 239000013256 coordination polymer Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical class CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- 229920001661 Chitosan Chemical class 0.000 claims description 4
- 108010010803 Gelatin Chemical class 0.000 claims description 4
- 229920002907 Guar gum Chemical class 0.000 claims description 4
- 239000008273 gelatin Chemical class 0.000 claims description 4
- 229920000159 gelatin Chemical class 0.000 claims description 4
- 229940014259 gelatin Drugs 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000000665 guar gum Chemical class 0.000 claims description 4
- 235000010417 guar gum Nutrition 0.000 claims description 4
- 229960002154 guar gum Drugs 0.000 claims description 4
- 239000000661 sodium alginate Chemical class 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical class OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 229920000161 Locust bean gum Chemical class 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 239000001913 cellulose Chemical class 0.000 claims description 3
- 229920002678 cellulose Chemical class 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000007938 effervescent tablet Substances 0.000 claims description 3
- 239000007888 film coating Substances 0.000 claims description 3
- 238000009501 film coating Methods 0.000 claims description 3
- 229940040145 liniment Drugs 0.000 claims description 3
- 239000000865 liniment Substances 0.000 claims description 3
- 239000000711 locust bean gum Chemical class 0.000 claims description 3
- 235000010420 locust bean gum Nutrition 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- VVRQVWSVLMGPRN-UHFFFAOYSA-N oxotungsten Chemical class [W]=O VVRQVWSVLMGPRN-UHFFFAOYSA-N 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 239000000230 xanthan gum Chemical class 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229920001285 xanthan gum Chemical class 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- 229940045110 chitosan Drugs 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 abstract description 60
- 230000000694 effects Effects 0.000 abstract description 19
- 239000003814 drug Substances 0.000 abstract description 14
- 241000894006 Bacteria Species 0.000 abstract description 11
- 239000003443 antiviral agent Substances 0.000 abstract description 11
- 244000000010 microbial pathogen Species 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 10
- -1 medical devices Substances 0.000 abstract description 8
- 210000004877 mucosa Anatomy 0.000 abstract description 8
- 230000002147 killing effect Effects 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 239000000645 desinfectant Substances 0.000 abstract description 3
- 230000004044 response Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 30
- PQQKPALAQIIWST-UHFFFAOYSA-N oxomolybdenum Chemical compound [Mo]=O PQQKPALAQIIWST-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000010998 test method Methods 0.000 description 9
- 241000222122 Candida albicans Species 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 229940095731 candida albicans Drugs 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 208000009608 Papillomavirus Infections Diseases 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 230000003385 bacteriostatic effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- QGLKJKCYBOYXKC-UHFFFAOYSA-N nonaoxidotritungsten Chemical compound O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1 QGLKJKCYBOYXKC-UHFFFAOYSA-N 0.000 description 5
- 238000011056 performance test Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- PBYZMCDFOULPGH-UHFFFAOYSA-N tungstate Chemical compound [O-][W]([O-])(=O)=O PBYZMCDFOULPGH-UHFFFAOYSA-N 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- XAEWLETZEZXLHR-UHFFFAOYSA-N zinc;dioxido(dioxo)molybdenum Chemical compound [Zn+2].[O-][Mo]([O-])(=O)=O XAEWLETZEZXLHR-UHFFFAOYSA-N 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 229910015667 MoO4 Inorganic materials 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 201000010153 skin papilloma Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 238000004435 EPR spectroscopy Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 2
- 229940043234 carbomer-940 Drugs 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003889 chemical engineering Methods 0.000 description 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 229960002751 imiquimod Drugs 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- AWOORJZBKBDNCP-UHFFFAOYSA-N molybdenum;oxotungsten Chemical compound [Mo].[W]=O AWOORJZBKBDNCP-UHFFFAOYSA-N 0.000 description 2
- 229960002566 papillomavirus vaccine Drugs 0.000 description 2
- 229960001237 podophyllotoxin Drugs 0.000 description 2
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 2
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 2
- 239000013460 polyoxometalate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- CMPGARWFYBADJI-UHFFFAOYSA-L tungstic acid Chemical compound O[W](O)(=O)=O CMPGARWFYBADJI-UHFFFAOYSA-L 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010044002 Tonsil cancer Diseases 0.000 description 1
- 208000006842 Tonsillar Neoplasms Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000004964 aerogel Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000004666 bacterial spore Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000004766 cell nucleus structure Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000004306 epidermodysplasia verruciformis Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000007561 laser diffraction method Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 229960005321 mecobalamin Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- MGRWKWACZDFZJT-UHFFFAOYSA-N molybdenum tungsten Chemical compound [Mo].[W] MGRWKWACZDFZJT-UHFFFAOYSA-N 0.000 description 1
- VLAPMBHFAWRUQP-UHFFFAOYSA-L molybdic acid Chemical compound O[Mo](O)(=O)=O VLAPMBHFAWRUQP-UHFFFAOYSA-L 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000003863 physical function Effects 0.000 description 1
- 238000013031 physical testing Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides the use of molybdenum and/or tungsten containing compounds in the treatment of human papillomavirus HPV or herpes virus HSV. The molybdenum and/or tungsten-containing compound of the invention can be used as an antiviral substance to rapidly kill and durably inhibit pathogenic microorganisms (bacteria, viruses and molds) and multidrug-resistant bacteria; can treat and relieve various symptoms caused by Human Papilloma Virus (HPV) and herpes virus (HSV), has quick response and strong virus killing activity, and antiviral substances are not absorbed by human bodies and do not generate toxic or side effect; can be used for reducing the load of Human Papillomavirus (HPV) and herpes virus (HSV) on local parts of a human body, and can also be used for preparing medicines, medical devices, disinfectants and other auxiliary care products for treating various human skin or skin mucosa diseases caused by pathogenic microorganisms.
Description
Technical Field
The invention belongs to the field of biological medicines, and particularly relates to application of a molybdenum and/or tungsten-containing compound in resisting Human Papilloma Virus (HPV) or herpes virus (HSV) and a pharmaceutical composition thereof.
Background
Scientific research finds that dermatosis caused by microorganisms, such as psoriasis, Human Papilloma Virus (HPV), herpes virus (HSV) and other lesions, are caused by the reproduction and growth of pathogenic microorganisms (bacteria, fungi and viruses) on the skin. The diseases have the advantages of wide population, large number of people, long duration, high recurrence rate, difficult radical cure and no specific medicine, and bring serious harm to the health and life of people. Currently, the main way to treat fungal infections is to apply hormonal drugs (e.g. ketoconazole) to the affected area, and the potential disadvantages include: the toxicity and the sensitization of the components easily cause the hyperfunction of the cortex, the treatment course is long, the effect is slow and the like.
For low-risk human papilloma virus HPV infection, some medicines have certain effects. Such as imiquimod, is an immunomodulator that acts by modulating the cellular immune function locally at the lesion; podophyllotoxin can inhibit virus and prevent cell proliferation caused by virus. However, for high-risk HPV infection, no antiviral drug which is proved to be fully effective by clinical practice is on the market at present. Some physicians attempt to treat high-risk HPV infections with interferon and may be theoretically effective, but it is not clearly concluded whether it is effective. Therefore, no specific drug is recommended for direct killing of HPV virus in the current clinical guidelines for the treatment of cervical lesions. The HPV vaccine has a certain prevention effect, but the existing HPV vaccine not only has age limitation, but also cannot completely cover the typing of the high-risk HPV (the high-risk HPV has at least 15 types, and the existing vaccine can cover at most 9 types), and the effective period of the vaccine is only 6-8 years.
Because there is no medicine capable of directly killing herpes virus, the treatment principle of herpes virus HSV infection is to take antiviral medicine, such as acyclovir, take mecobalamin to nourish nerve and relieve pain, and prevent complications such as postherpetic neuralgia. Long-term administration of the antiviral drug acyclovir may cause damage to liver or kidney function. Symptoms such as arthralgia, diarrhea, headache, nausea, vomiting, dizziness, etc. appear.
Disclosure of Invention
In view of the above problems in the prior art, the present invention provides the use of molybdenum and/or tungsten metal oxide, or molybdenum and/or tungstate, or polyoxometallate containing molybdenum and/or tungsten in resisting Human Papillomavirus (HPV) or herpes virus (HSV), and pharmaceutical compositions thereof.
Specifically, the present invention relates to the following aspects:
1. use of molybdenum-and/or tungsten-containing compounds against human papillomavirus HPV or herpes virus HSV.
2. The use according to item 1, wherein the molybdenum and/or tungsten-containing compound is one or more selected from the group consisting of an oxide of molybdenum and/or tungsten, a tungstate of molybdenum and/or tungsten, and a polyoxometalate of molybdenum and/or tungsten.
3. Use according to item 2, characterized in that the polyoxometallate containing molybdenum and/or tungsten is a tungsten molybdate.
4. The use according to item 1, wherein the anti-HPV is selected from the group consisting of anti-HPV high-risk type HPV or anti-HPV low-risk type HPV, wherein the anti-HPV high-risk type HPV is selected from one or more of HPV-1, HPV-2, HPV-3, HPV-4, HPV-7, HPV-10, HPV-12, HPV-15, HPV-16, HPV-18, HPV-30, HPV-31, HPV-33, HPV-35, HPV-39, HPV-53 and HPV-61, preferably HPV-16, HPV18 or HPV31, and the anti-HPV low-risk type HPV is selected from the group consisting of HPV-6, HPV-11, HPV-40, HPV-42, HPV-43, HPV-44, HPV-54, HPV-61, One or more of HPV-70, HPV-72, HPV-81 and CP 6108, preferably HPV-6 or HPV 11.
5. The use according to item 1, wherein the herpes virus HSV is selected from one or more of herpes simplex virus HSV-1, herpes simplex virus HSV-2, varicella-zoster virus VZV, epstein barr virus EBV, human cytomegalovirus HCMV, human herpesvirus 6 HHV-6, human herpesvirus 7 HHV-7, and kaposi's sarcoma-associated virus KSHV, preferably herpes simplex virus HSV or varicella-zoster virus VZV.
6. A pharmaceutical composition comprising a molybdenum and/or tungsten containing compound, wherein the molybdenum and/or tungsten containing compound is selected from one or more of molybdenum and/or tungsten oxides, molybdenum and/or tungstates, and molybdenum and/or tungsten containing polyoxometallates.
7. The pharmaceutical composition of item 6, wherein the pharmaceutical composition is a gel.
8. The pharmaceutical composition according to item 7, wherein the content of the molybdenum and/or tungsten containing compound in the gel is 0.05 to 30 wt%, preferably 0.1 to 1.0 wt%.
9. The pharmaceutical composition according to item 7, wherein the matrix of the gel is one or more selected from carbomer, gelatin, xanthan gum, locust bean gum, guar gum, chitosan, sodium alginate, cellulose derivatives, glycerol, polyethylene glycol (PEG), polyvinylpyrrolidone (PVP).
10. The pharmaceutical composition of item 6, wherein the molybdenum and/or tungsten containing compound is a tungsten molybdate.
11. The pharmaceutical composition according to item 10, wherein the tungsten molybdate is present in the pharmaceutical composition in the form of solid particles having a particle size of 10nm to 50 μm.
12. The pharmaceutical composition according to item 6, wherein the pharmaceutical composition or the functional dressing is in the form of an ointment, a solution, a powder, a liniment, a drop, a cream, a suppository, a paste, a spray, a film coating agent, a lotion, a water aqua, an effervescent tablet, a tape-shaped agent or a patch.
13. The pharmaceutical composition according to item 6, wherein the pharmaceutical composition is for use against Human Papillomavirus (HPV) or herpes virus (HSV).
14. The pharmaceutical composition according to item 13, wherein the anti-HPV is selected from the group consisting of anti-HPV high-risk type HPV or anti-HPV low-risk type HPV, wherein the anti-HPV high-risk type HPV is selected from the group consisting of HPV-1, HPV-2, HPV-3, HPV-4, HPV-7, HPV-10, HPV-12, HPV-15, HPV-16, HPV-18, HPV-30, HPV-31, HPV-33, HPV-35, HPV-39, HPV-53 and HPV-61, preferably is HPV-16, HPV18 or HPV31, and the anti-HPV low-risk type is selected from the group consisting of HPV-6, HPV-11, HPV-40, HPV-42, HPV-43, HPV-44, HPV-54, HPV-61, HPV-7, HPV-12, HPV-16, HPV-11, HPV-18, HPV-30, HPV-31, HPV-3, HPV-42, HPV-43, HPV-44, HPV-54, HPV-61, or HPV-61, One or more of HPV-70, HPV-72, HPV-81 and CP 6108, preferably HPV-6 or HPV 11.
15. The pharmaceutical composition according to item 13, wherein the herpes virus HSV is selected from one or more of herpes simplex virus type 1 HSV-1, herpes simplex virus type 2 HSV-2, varicella-zoster virus VZV, epstein barr virus EBV, human cytomegalovirus HCMV, human herpesvirus type 6 HHV-6, human herpesvirus type 7 HHV-7, and kaposi's sarcoma-associated virus KSHV, preferably herpes simplex virus HSV or varicella-zoster virus VZV.
The compounds containing molybdenum and/or tungsten of the invention can quickly kill and durably inhibit pathogenic microorganisms (bacteria, fungi and viruses) and multi-drug-resistant bacteria, has quick response, high efficiency and strong virus killing activity for resisting viruses, particularly Human Papilloma Virus (HPV) and herpes virus (HSV), and can not be absorbed by human body and generate toxic or side effect. The product is used for resisting Human Papilloma Virus (HPV) and herpes virus (HSV), and can also be used for preparing medicines, medical devices, disinfectants and other auxiliary care products for treating various human skin or skin mucosa diseases caused by pathogenic microorganisms.
Detailed Description
The present invention is further illustrated by the following examples, which are intended to be purely exemplary of the invention and are not intended to be limiting.
Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Although methods and materials similar or equivalent to those described herein can be used in experimental or practical applications, the materials and methods are described below. In case of conflict, the present specification, including definitions, will control, and the materials, methods, and examples are illustrative only and not intended to be limiting. The present invention is further illustrated by the following examples, which are not intended to limit the scope of the invention.
The present invention provides the use of molybdenum and/or tungsten containing compounds in the treatment of human papillomavirus HPV or herpes virus HSV.
Human papillomavirus HPV is a papillomavirus A belonging to the family papovaviridae, a papillomavirus A genus, a spherical DNA virus, which causes the proliferation of the squamous epithelium of the human skin mucosa. More than 130 types have been isolated, with different types leading to different clinical manifestations. Different types cause different clinical manifestations, and can be classified into (1) skin low-risk type: including HPV-1, 2, 3, 4, 7, 10, 12, 15, etc., associated with common warts, flat warts, plantar warts, etc.; (2) skin high risk type: including HPV-5, 8, 14, 17, 20, 36, 38, are associated with epidermodysplasia verruciformis, and other malignancies also associated with possible HPV infections include: vulvar, penile, anal, prostate, bladder cancer; (3) mucosal low risk types such as HPV-6, 11, 13, 32, 34, 40, 42, 43, 44, 54, etc. and infected genital, anal, oropharyngeal, and esophageal mucosa; (4) mucosa high-risk HPV-16, 18, 30, 31, 33, 35, 53 and 39 and cervical cancer, rectal cancer, oral cancer, tonsil cancer and the like. The present invention provides the use of molybdenum and/or tungsten containing compounds against human papillomavirus HPV.
Herpes viruses HSV (herpes viruses) are a type of enveloped virus whose genome is double-stranded DNA. There are 8 types of herpes viruses currently found to infect humans, including: herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), Varicella Zoster Virus (VZV), EB virus (Epstein-Barr virus, EBV), Human Cytomegalovirus (HCMV), human herpes virus type 6 (HHV-6), human herpes virus type 7 (HHV-7) and Kaposi's sarcoma-associated virus (KSHV). Patients and healthy carriers are sources of infection, primarily through direct intimate and sexual contact. HSV invades the body through various ways such as oral cavity, respiratory tract, genital tract mucosa and damaged skin. Human infection is very common, the infection rate reaches 80-90%, the common clinical manifestation is herpes accumulated on local mucosa or skin, and occasionally serious systemic diseases can also occur and viscera can be affected. The invention provides the use of molybdenum and/or tungsten containing compounds against herpes virus HSV.
Wherein "molybdenum and/or tungsten containing compound" as used herein refers to a molybdenum containing compound, a tungsten containing compound, or a molybdenum and tungsten containing compound.
In a preferred embodiment, the molybdenum and/or tungsten containing compound is selected from one or more of oxides, tungstates, and polyoxometallates of molybdenum and/or tungsten. Wherein, the oxide of molybdenum and/or tungsten can be tungsten oxide and molybdenum oxide. The molybdenum and/or tungstate may be molybdate, tungstate. The polyoxometallate comprising molybdenum and tungsten may be a tungsten polyoxometallate.
Polyoxometalates (POMs) are a class of polyoxometalate compounds formed by the attachment of early transition metal ions through oxygen. Polyoxometalates range primarily from higher valence early transition metals (primarily V, Nb, Ta, Mo, W) with the ability to form metal-oxygen cluster anions. After the 20 th century and the 70 th era, with the improvement of scientific level, especially with the leap development of electronic computer technology, the detection sensitivity and speed of a physical testing instrument processed by computer data are greatly improved, the amount of information provided is greatly increased, and the development of polyacid chemistry is greatly promoted. As a multinuclear complex containing an oxygen bridge, various related researches are increasingly emphasized by people. The interactions between metal ions through electron transfer in these systems and their coordination and influence with the bridging groups, end-group ligands, make them exhibit many different physical functions, chemical properties and biological activities from those of mononuclear complexes. The synthesis of polyacid compounds enters the stage of cutting and assembling rapid development, a large number of polyacid compounds with novel structures are synthesized, the high polymerization degree, chain type, micropore, layered polyacid complex and nano structure, sandwich type, inorganic double helix polyacid complex are layered, the synthesis and development of functional polyacid compounds are still the power for the great development of polyacid chemistry, and the functionalization of polyoxometallate almost relates to all fields, such as catalysis, photoelectromagnetic functional materials and medicinal chemistry, in particular to the research of antivirus, antitumor and AIDS resistance.
Among them, tungsten molybdate has an antiviral effect as a member of polyoxometallate, which effectively kills bacteria, viruses and molds by virtue of quadruple antimicrobial activity generated in situ. The 1 st activity, forming acidified water molecules which can be permanently reserved on the surface of an object on the surface of the object, thereby forming a weak acid environment with a lower pH value, effectively inhibiting the cell growth process, destroying a microbial phospholipid membrane and realizing protein denaturation; as the potential of the viral membrane decreases, no more effective energy is generated, causing membrane damage. The 2 nd type of activity can react with water on the surface of an object and in the air to generate active substances such as active oxygen (peroxide anions) and hydroxyl radicals to form free radicals. The active hydroxyl group is a strong oxidizing agent, and has decomposing and inactivating effects on nucleic acids, proteins and metabolic enzymes of bacteria, resulting in the death of microorganisms. 3 rd Activity, using electron paramagnetic resonance spectrometer EPR to detect Mo on the surface of tungsten molybdate object5+The metal cations exceed the living range of various pathogenic microorganisms due to the low pH value, so that the living environment of the microorganisms is seriously damaged, the cell membrane permeability of the microorganisms is enhanced, and cell metabolic enzymes and the cell nucleus structure are damaged by the rapid penetration of the hydrogen ions and the metal cations, thereby killing the microorganisms. Activity No. 4: the tungstomolyoxometalate antiviral agent exhibits high antiviral activity. The high Zeta potential of the tungsten molybdate is an important factor for generating electrostatic action, and the energy of electrostatic combination is strong, so that the tungsten molybdate is stable. Therefore, the excellent antiviral activity can be generated. Can kill various pathogenic microorganisms including MRSA and bacterial spores, and has the characteristics of high efficiency, rapidness, broad spectrum, durability, environmental protection and the like.
Tungsten molybdate as antiviral substance and water moleculeMolybdic acid and/or tungstic acid, and other by-products generated by the reaction, reduce the pH value of the skin contacted with the antiviral substance; meanwhile, antiviral substances can generate free radicals (such as superoxide radical and hydroxyl radical) and positive Zeta potential. The above mechanisms can produce synergistic effect, thereby achieving the effect of broad-spectrum and high-efficiency anti-pathogenic microorganisms. For example, molybdenum oxide reacts with water to form molybdic acid (H)2MoO4) Which in turn is reacted with H2Reaction of O to form H3O+And MoO4 -Or MoO4 2-. Tungsten oxide is also H2Formation of tungstic acid (H) from O2WO4) Of which is in contact with H2Reaction of O to form H3O+And WO4 -Or WO4 2-。
In a specific embodiment, the anti-human papillomavirus HPV is selected from anti-human papillomavirus high risk type HPV or anti-human papillomavirus low risk type HPV, wherein the anti-human papillomavirus high risk type HPV is selected from one or more of HPV-1, HPV-2, HPV-3, HPV-4, HPV-7, HPV-10, HPV-12, HPV-15, HPV-16, HPV-18, HPV-30, HPV-31, HPV-33, HPV-35, HPV-39, HPV-53 and HPV-61, preferably HPV-16, HPV18 or HPV31, and the anti-human papillomavirus low risk type HPV is selected from HPV-6, HPV-11, HPV-40, HPV-42, HPV-43, HPV-44, HPV-54, HPV-61, HPV-70, HPV-42, HPV-6, HPV-11, HPV-40, HPV-42, HPV-43, HPV-44, HPV-54, HPV-61, HPV-70, One or more of HPV-72, HPV-81 and CP 6108, preferably HPV-6 or HPV 11.
In a specific embodiment, the herpes virus HSV is selected from one or more of herpes simplex virus HSV-1, herpes simplex virus HSV-2, varicella-zoster virus VZV, EBV, human cytomegalovirus HCMV, human herpes virus HHV-6, human herpes virus HHV-7 and Kaposi sarcoma-associated virus KSHV, preferably herpes simplex virus HSV or varicella-zoster virus VZV.
The invention also provides a pharmaceutical composition which comprises a molybdenum and/or tungsten containing compound, wherein the molybdenum and/or tungsten containing compound is selected from one or more of molybdenum and/or tungsten oxide, molybdenum and/or tungstate and molybdenum and/or tungsten polyoxometallate.
The molybdenum and/or tungsten containing compounds may be used in combination with other oxides or salts. Other oxides or salts, including, but not limited to, alumina, silica, zirconia, tungsten oxide, titania, zinc molybdate, and the like. Taking molybdenum oxide as an example, the combination form of the molybdenum oxide and other oxides can be as follows: molybdenum oxide/tungsten oxide mixtures, molybdenum oxide/zinc molybdate mixtures, and the like. The combination may be mixing, dispersing, stirring, etc.
The form of the pharmaceutical composition of the present invention is not limited, and in a specific embodiment, the pharmaceutical composition is a gel. Under certain conditions, colloidal particles or macromolecules in a sol or solution are connected with each other to form a spatial network structure, and the structural voids are filled with a liquid (in a xerogel, a gas can be used, and the xerogel is also called an aerogel) serving as a dispersion medium, so that a special dispersion system is called a gel.
In a particular embodiment, the content of the molybdenum and/or tungsten containing compound in the gel is 0.05 to 30 wt%, for example 0.05 wt%, 0.1 wt%, 0.5 wt%, 1 wt%, 2 wt%, 3 wt%, 4 wt%, 5 wt%, 6 wt%, 7 wt%, 8 wt%, 9 wt%, 10 wt%, 15 wt%, 20 wt%, 25 wt%, 30 wt%, preferably 0.1 to 1.0 wt%.
The matrix of the gel can be one or more selected from carbomer, gelatin, guar gum, xanthan gum, locust bean gum, chitosan, sodium alginate, cellulose derivatives, glycerol, polyethylene glycol (PEG), and polyvinylpyrrolidone (PVP).
In a particular embodiment, the molybdenum and/or tungsten containing compound in the pharmaceutical composition is a tungsten molybdate.
In a particular embodiment, the tungsten molybdate is present in the pharmaceutical composition in the form of solid particles, said particles having a particle size of 10nm to 50 μm. The particle size of the tungsten molybdate particles can be measured by using a sieving method, a laser diffraction method or a microscope image method, for example, the tungsten molybdate particles can exist in the form of solid particles, especially micron-sized solid particles, in the pharmaceutical composition in the form of 10nm, 50nm, 100nm, 1 μm, 5 μm, 10 μm, 20 μm and 50 μm, and the tungsten molybdate is not absorbed by human tissues and therefore does not generate toxicity. In a specific embodiment, the above combination of gel forms is prepared according to the following method: adding a compound containing molybdenum and/or tungsten into a gel matrix, uniformly stirring, adding purified water and a neutralizing agent, uniformly mixing to form gel, and standing. Wherein the pH value of the gel is 1-7, and can be 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5 and 7. Preferably, the pH value ranges from 3 to 6.5; more preferably, the pH ranges from 4.5 to 6; most preferably, the pH range is 4.5-5.5.
The weak acid microenvironment on the surface of the gel can quickly kill and durably inhibit pathogenic microorganisms (bacteria, viruses and fungi) and multiple drug-resistant bacteria under the synergistic action of the multiple antiviral mechanisms, has quick response and lasting antiviral action time, and the antiviral agent is not absorbed by human body and does not generate toxic or side effect.
The pharmaceutical composition or functional dressing of the present invention may be administered in various dosage forms, for example, as an ointment, solution, powder, liniment, drop, cream, suppository, paste, spray, film coating agent, lotion, aqueous agent, effervescent tablet, tape, or patch.
The pharmaceutical composition also comprises pharmaceutically acceptable auxiliary materials. Such adjuvants are known in the art and may be preservatives, humectants, stabilizers, neutralizing agents and the like.
The pharmaceutical composition is used for resisting Human Papilloma Virus (HPV) or herpes virus (HSV). Wherein the selection against human papillomavirus HPV and herpes virus HSV is as described above for the use of molybdenum and/or tungsten containing compounds.
The compound and the pharmaceutical composition containing molybdenum and/or tungsten of the invention have the advantages of antibiosis and antivirus by means of multiple mechanisms, no toxic or side effect, effective resistance to common pathogenic microorganisms and super bacteria, and the antibacterial rate to escherichia coli and staphylococcus aureus is more than 99.2 percent, and the antibacterial rate to candida albicans is more than 95.5 percent; the antiviral agent is safe and harmless, does not change the cell genetic characteristics, does not cause cancer, does not generate drug resistance, and is efficient and durable in antiviral; can be used for resisting Human Papilloma Virus (HPV) or herpes virus (HSV), has antiviral activity rate of more than 99.9%, and can also be used for preparing medicines, medical devices, disinfectants and other auxiliary care products for treating various human skin or skin mucosa diseases caused by pathogenic microorganisms.
Examples
Example 1
Preparing a molybdenum oxide aqueous solution with the mass concentration of 0.45%, adding 0.5g of tungsten molybdate into 95.5ml of the molybdenum oxide aqueous solution for uniform dispersion, adding 3.0g of carbomer 940 and 1.0g of glycerol as gel substrates, mixing, uniformly stirring, and standing for 2 hours to obtain the antiviral gel. Wherein the particle size of the tungsten molybdate in the gel is 2 μm, and the pH value of the antiviral gel is 4.5.
The prepared antiviral gel is subjected to an antibacterial performance test by committing Guangzhou city microbiology research institute limited company according to national sanitation industry standard WS/T650-2019 antibacterial and bacteriostatic effect evaluation method, and the result shows that the antibacterial rate of the antiviral gel to escherichia coli and staphylococcus aureus is more than 99.9%, and the antibacterial rate to candida albicans is 99.1%. Has strong antibacterial effect.
The prepared antiviral gel is placed in a thermostat at 54-57 ℃ for 14 days according to a test method specified in appendix C of national standard GB 15979-1995 hygienic Standard for Disposable hygienic articles, and then sterilization performance is tested. The results show that the antibacterial stability is not less than 1 year.
The prepared antiviral gel was tested against human papillomavirus HPV16 (host name: Vero-E6 cell) by Shanghai micro-spectral chemical engineering services, Inc., Committed in technical Specification for Disinfection (2002) for antiviral activity. The results show that the antiviral gel has an antiviral activity value of 3.01 in 2 hours and an antiviral activity rate of more than 99.9%.
Example 2
Adding 0.5g of tungsten molybdate into gel matrix 1.0g of carbomer 940, stirring uniformly, adding 97.3ml of purified water, adding 0.2g of neutralizing agent triethanolamine, stirring uniformly for forming, adding 1.0g of glycerol, stirring uniformly, and standing for 2 hours to obtain the antiviral gel. Wherein the particle size of the tungsten-molybdenum-oxygen acid in the gel is 2 μm, and the pH value of the antiviral gel is 5.5.
The prepared antiviral gel is subjected to an antibacterial performance experiment according to the national sanitation industry standard WS/T650 plus 2019 'antibacterial and bacteriostatic effect evaluation method', and the result shows that the antibacterial rate of the antiviral gel to escherichia coli and staphylococcus aureus is greater than 99.20%, and the antibacterial rate to candida albicans is greater than 95.5%.
The prepared antiviral gel is put in an incubator at 54-57 ℃ for 14 days according to a test method specified in appendix C of national standard GB 15979-1995 hygienic Standard for Disposable sanitary articles or other test methods specified in international standards, national standards or industry standards with the same efficacy, and a sterilization performance test result shows that the antibacterial stability is not less than 1 year.
The prepared antiviral gel was tested by Shanghai micro-spectral chemical engineering service Co., Ltd according to Sterilization Specification (2002) to detect the anti-herpes virus activity of the antiviral gel against herpes simplex virus HSV-2 (host name: Vero-E6 cell). The results showed that the antiviral gel had an antiviral activity value of 4.03 for 2 hours and an antiviral activity rate of more than 99.99%.
Example 3
Adding 0.8g of tungsten molybdate into 4.0g of guar gum as gel matrix, stirring uniformly, adding 94.2ml of purified water and 1.0g of glycerol, stirring uniformly and forming to obtain the antiviral gel. Wherein the particle size of the tungsten-molybdenum-oxygen acid in the gel is 2 μm, and the pH value of the antiviral gel is 6.0.
The prepared antiviral gel is subjected to an antibacterial performance experiment according to the national sanitation industry standard WS/T650 plus 2019 antibacterial and bacteriostatic effect evaluation method, and the result shows that the antibacterial rate of the antiviral gel to escherichia coli and staphylococcus aureus is greater than 99.50%, and the antibacterial rate to candida albicans is greater than 95.85%.
The prepared antiviral gel is put in an incubator at 54-57 ℃ for 14 days according to a test method specified in appendix C of national standard GB 15979-1995 hygienic Standard for Disposable sanitary articles or other test methods specified in international standards, national standards or industry standards with the same efficacy, and a sterilization performance test result shows that the antibacterial stability is not less than 1 year.
The prepared antiviral gel was tested according to technical Specification for Disinfection (2002), and the antiviral activity of the antiviral gel was examined against human papillomavirus HPV16 (host name: Vero-E6 cell). The results show that the antiviral gel has an antiviral activity value of 3.05 in 2 hours and an antiviral activity rate of more than 99.9%.
Example 4
0.6g of molybdenum oxide powder and 0.4g of zinc molybdate powder are dissolved in 73ml of purified water and stirred uniformly. And adding 5.0g of chitosan and 20.0g of gelatin into the gel matrix, mixing, adding 1.0g of glycerol, standing, uniformly stirring and forming to obtain the antiviral gel. The particle size of the molybdenum oxide powder and the zinc molybdate powder was 1 μm. The pH of the antiviral gel was 3.5.
Antibacterial performance experiments are carried out on the prepared antiviral gel according to the national sanitary industry standard WS/T650 plus 2019 'evaluation method for antibacterial and bacteriostatic effects', and the results show that the antibacterial rates of the antiviral gel on escherichia coli and staphylococcus aureus are both more than 99.35%, and the antibacterial rate on candida albicans is more than 96.6%
The prepared antiviral gel is put in an incubator at 54-57 ℃ for 14 days according to a test method specified in appendix C of national standard GB 15979-1995 hygienic Standard for Disposable sanitary articles or other test methods specified in international standards, national standards or industry standards with the same efficacy, and a sterilization performance test result shows that the antibacterial stability is not less than 1 year.
The prepared antiviral gel was tested according to technical Specification for Disinfection (2002), and the antiviral activity of the antiviral gel was examined against human papillomavirus HPV16 (host name: Vero-E6 cell). The results show that the antiviral gel has an antiviral activity value of 3.01 in 2 hours and an antiviral activity rate of more than 99.9%.
Example 5
0.6g of tungsten-molybdenum oxysalt is put into 95.37ml of purified water for even dispersion, 0.03g of polyhexamethylene hydrochloric acid (PHMB) is added, 4.0g of sodium alginate is added into the gel matrix, and the mixture is stirred and formed evenly to obtain the antiviral gel. Wherein the particle size of the tungsten molybdate in the antiviral gel is 2 μm, and the pH value of the antiviral gel is 5.5.
The prepared antiviral gel is subjected to an antibacterial performance experiment according to the national sanitation industry standard WS/T650 plus 2019 antibacterial and bacteriostatic effect evaluation method, and the result shows that the antibacterial rate of the antiviral gel to escherichia coli and staphylococcus aureus is more than 99.75%, and the antibacterial rate to candida albicans is more than 96.5%.
The prepared antiviral gel is put in an incubator at 54-57 ℃ for 14 days according to a test method specified in appendix C of national standard GB 15979-1995 hygienic Standard for Disposable sanitary articles or other test methods specified in international standards, national standards or industry standards with the same efficacy, and a sterilization performance test result shows that the antibacterial stability is not less than 1 year.
Like most virus infections, HPV or HSV infection has high morbidity and is difficult to cure radically, and no specific medicine capable of directly killing HPV or HSV virus exists globally. In the market, various antiviral drugs indirectly inhibit viruses through an immune regulation or hormone (interferon) mode, and the effect of resisting HPV is not ideal or has no effect. For low-risk HPV infection, a plurality of medicines have certain effects. Such as imiquimod, is an immunomodulator that acts by modulating the cellular immune function locally at the lesion; podophyllotoxin can inhibit virus and prevent cell proliferation caused by virus. However, no effective antiviral drug is available on the market for high-risk HPV infection. Therefore, no specific drug is recommended for direct killing of HPV virus in current clinical guidelines for the treatment of cervical lesions. The effective component of the gel product for resisting high-risk HPV virus in the market is beta-glucan interferon or animal ovoglobulin. The treatment of HPV by using interferon has long period, side effect and undesirable effect; the use of the animal ovovitellin is not only very costly, but also unsatisfactory in efficacy.
The compound containing molybdenum and/or tungsten and the pharmaceutical composition have no toxic or side effect, can effectively resist common pathogenic microorganisms and super bacteria, and have the antibacterial rate of more than 99.2 percent on escherichia coli and staphylococcus aureus and the antibacterial rate of more than 95.5 percent on candida albicans; the antiviral agent is safe and harmless, does not change the cell genetic characteristics, does not cause cancer, does not generate drug resistance, and is efficient and durable in antiviral; can be used for resisting Human Papilloma Virus (HPV) or herpes virus (HSV), and has antiviral activity rate of more than 99.9%.
Claims (10)
1. Use of molybdenum-and/or tungsten-containing compounds against human papillomavirus HPV or herpes virus HSV.
2. Use according to claim 1, wherein the molybdenum and/or tungsten containing compound is selected from one or more of molybdenum and/or tungsten oxides, molybdenum and/or tungstates, and molybdenum and/or tungsten containing polyoxometallates.
3. Use according to claim 2, characterized in that the polyoxometallate containing molybdenum and/or tungsten is tungsten molybdate.
4. The use according to claim 1, wherein the anti-HPV is selected from the group consisting of anti-HPV high-risk type selected from HPV-1, HPV-2, HPV-3, HPV-4, HPV-7, HPV-10, HPV-12, HPV-15, HPV-16, HPV-18, HPV-30, HPV-31, HPV-33, HPV-35, HPV-39, HPV-53 and HPV-61, preferably HPV-16, HPV18 and HPV31, or anti-HPV low-risk type selected from HPV-6, HPV-11, HPV-40, HPV-42, HPV-43, HPV-44, HPV-54, HPV-61, One or more of HPV-70, HPV-72, HPV-81 and CP 6108, preferably HPV-6 or HPV11, or
The herpes virus HSV is selected from one or more than two of herpes simplex virus 1 type HSV-1, herpes simplex virus 2 type HSV-2, varicella-zoster virus VZV, EB virus EBV, human cytomegalovirus HCMV, human herpes virus 6 type HHV-6, human herpes virus 7 type HHV-7 and Kaposi sarcoma related virus KSHV, and is preferably herpes simplex virus HSV or varicella-zoster virus VZV.
5. A pharmaceutical composition comprising a molybdenum and/or tungsten containing compound, wherein the molybdenum and/or tungsten containing compound is selected from one or more of molybdenum and/or tungsten oxides, molybdenum and/or tungstates, and molybdenum and/or tungsten containing polyoxometallates, preferably the molybdenum and/or tungsten containing compound is a tungsten molybdenate.
6. Pharmaceutical composition according to claim 5, wherein the pharmaceutical composition is a gel, preferably wherein the content of the molybdenum and/or tungsten containing compound in the gel is 0.05-30 wt.%, preferably 0.1-1.0 wt.%.
7. The pharmaceutical composition of claim 6, wherein the matrix of the gel is one or more selected from carbomer, gelatin, xanthan gum, locust bean gum, guar gum, chitosan, sodium alginate, cellulose derivatives, glycerol, polyethylene glycol (PEG), polyvinylpyrrolidone (PVP).
8. The pharmaceutical composition of claim 5, wherein the tungsten molybdate is present in the pharmaceutical composition as solid particles having a particle size of 10nm to 50 μm.
9. The pharmaceutical composition of claim 5, wherein the pharmaceutical composition or functional dressing is in the form of an ointment, a solution, a powder, a liniment, drops, a cream, a suppository, a paste, a spray, a film coating agent, a lotion, an aqueous agent, an effervescent tablet, a tape-shaped agent or a patch.
10. The pharmaceutical composition of claim 5, wherein the pharmaceutical composition is for use against Human Papillomavirus (HPV) or herpes virus (HSV),
preferably, the anti-human papilloma virus HPV is selected from anti-human papilloma virus high-risk type HPV or anti-human papilloma virus low-risk type HPV, wherein the anti-human papilloma virus high-risk type HPV is selected from one or more of HPV-1, HPV-2, HPV-3, HPV-4, HPV-7, HPV-10, HPV-12, HPV-15, HPV-16, HPV-18, HPV-30, HPV-31, HPV-33, HPV-35, HPV-39, HPV-53 and HPV-61, preferably HPV-16, HPV18 or HPV31, and the anti-human papilloma virus low-risk type HPV is selected from HPV-6, HPV-11, HPV-40, HPV-42, HPV-43, HPV-44, HPV-54, HPV-61, HPV-70, HPV-72, HPV-81, One or more than two of CP 6108, preferably HPV-6 or HPV 11; or
Preferably, the herpes virus HSV is selected from one or more than two of herpes simplex virus HSV-1, herpes simplex virus HSV-2, varicella-zoster virus VZV, EBV, human cytomegalovirus HCMV, human herpes virus HHV-6, human herpes virus HHV-7 and Kaposi sarcoma related virus KSHV, and preferably is herpes simplex virus HSV or varicella-zoster virus VZV.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110961745.4A CN113577099A (en) | 2021-08-20 | 2021-08-20 | Use of molybdenum and/or tungsten containing compounds against Human Papilloma Virus (HPV) or herpes virus (HSV) and pharmaceutical compositions thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110961745.4A CN113577099A (en) | 2021-08-20 | 2021-08-20 | Use of molybdenum and/or tungsten containing compounds against Human Papilloma Virus (HPV) or herpes virus (HSV) and pharmaceutical compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113577099A true CN113577099A (en) | 2021-11-02 |
Family
ID=78238910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110961745.4A Pending CN113577099A (en) | 2021-08-20 | 2021-08-20 | Use of molybdenum and/or tungsten containing compounds against Human Papilloma Virus (HPV) or herpes virus (HSV) and pharmaceutical compositions thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113577099A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114469993A (en) * | 2022-02-15 | 2022-05-13 | 山西白求恩医院 | Preparation method and application of water-soluble organic hybrid polyoxometallate |
| CN114569717A (en) * | 2022-03-05 | 2022-06-03 | 广西博生生物科技有限公司 | anti-HPV virus yolk immunoglobulin gel and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101111247A (en) * | 2005-02-02 | 2008-01-23 | 安斯泰来制药有限公司 | Preventive or therapeutic agent for herpesvirus-related disease |
| US20180228749A1 (en) * | 2016-06-28 | 2018-08-16 | Mehmet Nevzat Pisak | Surfactants and compositions for treatment of viral skin conditions |
-
2021
- 2021-08-20 CN CN202110961745.4A patent/CN113577099A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101111247A (en) * | 2005-02-02 | 2008-01-23 | 安斯泰来制药有限公司 | Preventive or therapeutic agent for herpesvirus-related disease |
| US20180228749A1 (en) * | 2016-06-28 | 2018-08-16 | Mehmet Nevzat Pisak | Surfactants and compositions for treatment of viral skin conditions |
Non-Patent Citations (9)
| Title |
|---|
| BONDAREVA, E.V.等: "Equilibrium in molybdenum(Ⅵ)-hydronium(1+) system", 《ZHURNAL NEORGANICHESKOI KHIMII》, vol. 34, no. 12, pages 3196 - 200 * |
| G.M.MAKSIMOV等: "Acetonation of L-Sorbose in the presence of heteropolyacids", 《REACTION KINETICS AND CATALYSIS LETTERS》, vol. 56, no. 1, pages 191 - 196 * |
| MARIKO FUKUMA 等: "In vitro antiviral activity of polyoxotungstate (PM-19) and other polyoxometalates against herpes simplex virus", 《ANTIVIRAL RESEARCH》, pages 327 - 339 * |
| 刁畅等: "新型多金属氧酸盐配合物与HPV联合检测对抗宫颈癌作用的研究", 《世界最新医学信息文摘》 * |
| 刁畅等: "新型多金属氧酸盐配合物与HPV联合检测对抗宫颈癌作用的研究", 《世界最新医学信息文摘》, no. 80, 6 October 2017 (2017-10-06), pages 78 - 80 * |
| 刘杰 等: "多金属氧酸盐抗病毒药物研究", 《化学进展》, vol. 18, no. 1, pages 114 - 119 * |
| 刘杰等: "多金属氧酸盐抗病毒药物研究", 《化学进展》, no. 01, 24 January 2006 (2006-01-24) * |
| 甄如月等: "多金属氧酸盐及其衍生物在药物方面的研究进展", 《南华大学学报(自然科学版)》 * |
| 甄如月等: "多金属氧酸盐及其衍生物在药物方面的研究进展", 《南华大学学报(自然科学版)》, no. 02, 30 April 2020 (2020-04-30), pages 91 - 97 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114469993A (en) * | 2022-02-15 | 2022-05-13 | 山西白求恩医院 | Preparation method and application of water-soluble organic hybrid polyoxometallate |
| CN114569717A (en) * | 2022-03-05 | 2022-06-03 | 广西博生生物科技有限公司 | anti-HPV virus yolk immunoglobulin gel and preparation method thereof |
| CN114569717B (en) * | 2022-03-05 | 2023-11-14 | 广西博生生物科技有限公司 | Yolk immunoglobulin gel for resisting HPV virus and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113577099A (en) | Use of molybdenum and/or tungsten containing compounds against Human Papilloma Virus (HPV) or herpes virus (HSV) and pharmaceutical compositions thereof | |
| Tavakoli et al. | Polyethylene glycol-coated zinc oxide nanoparticle: an efficient nanoweapon to fight against herpes simplex virus type 1 | |
| EP3760192B1 (en) | Chloroquine gel and preparation method and application therefor | |
| AU2013299182B2 (en) | Physical antimicrobial method | |
| MX2008001673A (en) | Use of hydroxybenzoic acid ester and analogues for the manufacture of a mendicament for the prevention and treatment of virus infection. | |
| CN105031625A (en) | Charge modified lactoferrin and carrageenin combination medicine and preparation method thereof | |
| Chen et al. | Preparation, property of the complex of carboxymethyl chitosan grafted copolymer with iodine and application of it in cervical antibacterial biomembrane | |
| Thakur et al. | Futuristic role of nanoparticles for treatment of COVID-19 | |
| WO2002020486A2 (en) | Picolinic acid derivatives for the prevention and treatment of cancer in animals | |
| Yadav et al. | Antifungal Activity of Malvastrum Coromandelianum Leaf Extracts | |
| Niu et al. | A multi-targeted nanoconjugate for light-driven therapy of chronic wounds | |
| CN111617115A (en) | Combined medicine for preventing and treating mucosal virus infection and preparation method thereof | |
| JP2009508883A (en) | Use of Nocardia rubra cell wall skeleton in the preparation of anti-HPV infection drugs | |
| WO2017143980A1 (en) | Polyurethane material and preparation method thereof | |
| Pinto et al. | HPV in the male patient | |
| Tyring | Immune-response modifiers: A new paradigm in the treatment of human papillomavirus | |
| CN115715785A (en) | anti-HPV gel and production process thereof | |
| CN112402451A (en) | anti-HPV (human papilloma Virus) and HSV (herpes Simplex virus) medicine and preparation method thereof | |
| CN115154482B (en) | Application of ferric sulfide nano enzyme in resisting human papilloma virus | |
| Al-Musawi et al. | Titanium Dioxide Nanoparticles: A Novel Approach for Inhibiting Human Papillomavirus | |
| CN101874795A (en) | Application of 5-aminolevulinic acid in preparing medicaments for treating HPV (Human Papilloma Virus) infection | |
| Wang et al. | CuFeS2 nanozyme regulating ROS/GSH redox induces ferroptosis-like death in bacteria for robust anti-infection therapy | |
| Ostrow et al. | Topical CTC-96 accelerates wart growth in rabbits infected with cottontail rabbit papillomavirus | |
| Adetunji et al. | The role of carbon dots in combating various pathogens | |
| CN115400144A (en) | Boric acid and nitrite-containing anti-pathogenic microorganism composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |